CASE SNAPSHOT 01

Neurodegeneration / Early Development Readiness

Early neurodegeneration programs must generate more than safety data. They must preserve Phase II/III decision value.

CONTEXT

The situation

Early neurodegeneration programs require more than a safe Phase I protocol. They need a development architecture that translates safety, biomarker, pharmacodynamic, and clinical signals into a credible Phase II/III path.

DECISION CHALLENGE

What had to be resolved

High biological uncertainty
Limited early efficacy signal detectability
Complex endpoint selection
Need to align biomarkers, population, safety monitoring, and registrational feasibility

OUR INTERVENTION

What changed in the decision system

Built integrated clinical development logic from early safety to pivotal readiness
Defined endpoint, biomarker, and population strategy
Developed risk map and decision gates across clinical, regulatory, payer/HEOR, commercial, and operational domains

OUTCOMES

What the programme gained

Decision-grade development path from early data to Phase II/III planning
Stronger alignment between science, regulation, execution, and future value narrative

STRATEGIC IMPLICATION

Early-phase studies must be designed to create downstream decision value, not only early safety data.

RELATED CAPABILITY

Clinical Development Strategy

Translate early scientific signals into a development architecture that preserves the value of the next decision.

A SIMILAR DECISION?

Use the evidence before the next irreversible commitment.

Bring the live decision, the next hard milestone and the uncertainty that is currently exposed.